Clinical benefits of evolocumab appear less than hoped - Authors' reply

doi:10.1016/S0140-6736(18)30529-4

Comment

. 2018 Mar 10;391(10124):934-935.

doi: 10.1016/S0140-6736(18)30529-4.

Clinical benefits of evolocumab appear less than hoped - Authors' reply

Robert P Giugliano¹, Anthony C Keech², Peter S Sever³, Terje R Pedersen⁴, Marc S Sabatine⁵

Affiliations

¹ TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: rgiugliano@bwh.harvard.edu.
² Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
³ International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, UK.
⁴ Oslo University Hospital, Ullevål and Medical Faculty, University of Oslo, Oslo, Norway.
⁵ TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

PMID: 29536853
DOI: 10.1016/S0140-6736(18)30529-4

Free article

Comment

Clinical benefits of evolocumab appear less than hoped - Authors' reply

Robert P Giugliano et al. Lancet. 2018.

Free article

. 2018 Mar 10;391(10124):934-935.

doi: 10.1016/S0140-6736(18)30529-4.

Authors

Robert P Giugliano¹, Anthony C Keech², Peter S Sever³, Terje R Pedersen⁴, Marc S Sabatine⁵

Affiliations

¹ TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: rgiugliano@bwh.harvard.edu.
² Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
³ International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, UK.
⁴ Oslo University Hospital, Ullevål and Medical Faculty, University of Oslo, Oslo, Norway.
⁵ TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

PMID: 29536853
DOI: 10.1016/S0140-6736(18)30529-4

No abstract available

PubMed Disclaimer

Comment on

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Sabatine MS, et al. N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17. N Engl J Med. 2017. PMID: 28304224 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Clinical benefits of evolocumab appear less than hoped - Authors' reply

Affiliations

Clinical benefits of evolocumab appear less than hoped - Authors' reply

Authors

Affiliations

Comment on

Similar articles

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources